# US 2023/0174506 A1 · (di)amination of activated allene compounds, derivatives thereof, and methods for synthesis of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0174506 A1
- Document ID: US20230174506A1
- Status: Published application
- Kind: A1
- Application number: 18/060,922
- Filed: 2022-12-01
- Published: 2023-06-08
- Earliest claimed: 2021-12-01
- Assignees: Purdue Research Foundation
- Applicants: Purdue Research Foundation
- Inventors: Mingii DAI
- Web page: https://patentgrep.com/patent/US20230174506A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07C 229/34: the carbon skeleton containing six-membered aromatic rings
- C07D 209/50: with oxygen and nitrogen atoms in positions 1 and 3
- C07D 211/14: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 211/62: attached in position 4
- C07D 263/56: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 295/145: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 311/16: substituted in position 7
- C07D 333/34: Sulfur atoms
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07J 43/003: {not condensed}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07J: STEROIDS (seco-steroids C07C)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

One-pot synthesis methods for producing amines from activated allenes and derivatives thereof are provided, as well as the compounds produced thereby.

## Claims

### Claim 1

A method of synthesizing amines from activated allene compounds or derivatives thereof in a one-pot reaction comprising:
providing a solution comprising an electrophilic amine or an allene and an amine halogenating reagent and adding a first compound to the solution to carry out a first animation reaction, wherein the first compound comprises an electron-withdrawing group (EWG);
adding a nucleophilic reagent and a base to a reaction mixture of the animation reaction to carry out a second nucleophilic reaction; and
adding a reducing reagent to a reaction mixture of the nucleophilic reaction to carry out a third enamine reduction reaction and synthesize an amine product from an activated allene compound or derivative thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amine halogenating reagent comprises one or more of t-BuOCl, tetra-n-butylammonium iodide (TBAI), N-bromosuccinimide (NBS), N-Iodosuccinimide (NIS), N-Chlorosuccinimide (NCS), KI, and NaI.

### Claim 3 (depends on 2)

The method of claim 2, wherein the amine halogenating reagent comprises a mixture of t-BuOCl and TBAI.

### Claim 4 (depends on 1)

The method of claim 1, wherein the electrophilic amine is a cyclic aliphatic amine or an acyclic aliphatic amine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the electrophilic amine has a structure of the formula R3R4NH, wherein R3 and R4 are each independently an optionally substituted C1-C12 straight or branched alkyl, C2-C12 straight or branched alkenyl, C2-C12 straight or branched alkynyl, C3-C10 cycloalkyl, C3-C10 hetero cyclic ring, C5-C12 aryl, or C5-C12 heteroaryl.

### Claim 6 (depends on 5)

The method of claim 5, wherein the first compound has a structure of Formula I:
wherein:
R1 is H or F;
R2 is the EWG; and
in the product, the R2 of Formula II and the R3 of Formula I are joined together to form an optionally substituted heterocyclic ring.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nucleophilic reagent is a cyclic amine, an acyclic amine, an amide, a carbamate, an imide, or a sulfonamide.

### Claim 8 (depends on 7)

The method of claim 7, wherein the nucleophilic reagent has a structure of the formula HNR6R7 or HXR8, wherein:
X is O or S; and
R6, R7 and R8 are each independently an optionally substituted C1-C12 straight or branched alkyl, C2-C12 straight or branched alkenyl, C2-C12 straight or branched alkynyl, C3-C10 cycloalkyl, C3-C10 hetero cyclic ring, C5-C12 aryl, or C5-C12 heteroaryl.

### Claim 9 (depends on 8)

The method of claim 8, wherein R6 and R7 are joined together to form an optionally substituted heterocyclic ring.

### Claim 10 (depends on 1)

The method of claim 1, wherein the base is ceasium carbonate (Cs2CO3), potassium carbonate (K2CO3) or tetrahydrofuran (THF).

### Claim 11 (depends on 1)

The method of claim 1, wherein the reducing agent comprises NaBH3CN.

### Claim 12 (depends on 11)

The method of claim 11, further comprising adding a co-solvent of MeOH/AcOH to a reaction mixture of the reduction reaction.

### Claim 13 (depends on 1)

The method of claim 1, further comprising drying and purifying the activated allene compound or derivative thereof.

### Claim 14

A method of synthesizing a compound of formula II from a compound of formula I:
wherein:
R1 is H or F;
R2 is an electron-withdrawing group (EWG);
R3 and R4 are each independently an optionally substituted C1-C12 straight or branched alkyl, C2-C12 straight or branched alkenyl, C2-C12 straight or branched alkynyl, C3-C10 cycloalkyl, C3-C10 hetero cyclic ring, C5-C12 aryl, or C5-C12 heteroaryl, wherein R2 and R3 can join together to form an optionally substituted hetero cyclic ring;
R5 is —NR6R7 or —XR8, wherein R6, R7 and R8 are each independently an optionally substituted C1-C12 straight or branched alkyl, C2-C12 straight or branched alkenyl, C2-C12 straight or branched alkynyl, C3-C10 cycloalkyl, C3-C10 hetero cyclic ring, C5-C12 aryl, or C5-C12 heteroaryl,
wherein R6 and R7 can join together to form an optionally substituted hetero cyclic ring, and X is O or S; and
comprising:
providing a solution comprising a secondary amine R3R4NH and an amine halogenating reagent;
adding a compound of formula I to said solution to carry out a first electrophilic amination reaction;
adding a nucleophilic reagent HNR6R7 or HXR8, and a base to reaction mixture of the first electrophilic amination reaction to carry out a second nucleophilic reaction; and
adding a reducing reagent to reaction mixture of said second nucleophilic reaction to carry out a third enamine reduction reaction to provide the compound of formula II.

### Claim 15 (depends on 14)

The method of claim 14, wherein the amine halogenating reagent is t-BuOCl, tetra-n-butylammonium iodide (TBAI), N-bromosuccinimide (NBS), N-Iodosuccinimide (NIS), N-Chlorosuccinimide (NCS), KI, NaI, or any combination of two or more of the foregoing.

### Claim 16 (depends on 14)

The method of claim 14, wherein the method is a one-pot reaction.

### Claim 17 (depends on 14)

The method of claim 14, wherein the EWG comprises an aldehyde group, ketone group, carboxylic acid group, acyl group, ester group, amide group, trihalide group, cyano group, isocyano, sulfonyl group, nitro group, F, or Cl.

### Claim 18 (depends on 1)

A compound prepared by the method of claim 1, wherein the compound has a structure of Formula (III):
or is a pharmaceutically acceptable salt thereof, wherein
R1 is D or absent;
R2 is
wherein
Y is N, S, C, or O, and
R4 is Ph,
or absent; and
R3 is OBn, OEt,
X is
wherein R5 is Ph or COOMe; and
X1 is absent or F.

### Claim 19 (depends on 1)

A compound prepared by the method of claim 1, wherein the compound has a structure of Formula (IV):
or is a pharmaceutically acceptable salt thereof, wherein
X is
X2 is Ph,
X3 is

### Claim 20 (depends on 1)

A compound prepared by the method of claim 1, wherein the compound has a structure of Formula (V):
or is a pharmaceutically acceptable salt thereof, wherein:
X is O or S;
R7 is
R8 is
R9 is
and
R1 is absent or D.
